PRTA - Prothena plans IND filing for Alzheimer's candidate in 2023

Announcing preclinical data for its dual A?/tau vaccine targeted at Alzheimer’s disease, clinical-stage biotech Prothena Corporation (NASDAQ:PRTA) said on Wednesday that the company plans for an Investigational New Drug (IND) application for the candidate in 2023. In Addition, Prothena (PRTA) shared results from the delayed-start analysis of Phase 2 PASADENA study of prasinezumab, the ?-synuclein antibody being developed for Parkinson’s disease (PD) in partnership with Roche (OTCQX:RHHBY). The results indicated that patients treated with prasinezumab for two years (early-start group) showed a slower decline in scores of a key rating scale designed to measure various aspects of PD [Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part 3]. Last February, Prothena (PRTA) said that an IND filing for Alzheimer’s candidate PRX012 is expected in Q1 2022.

For further details see:

Prothena plans IND filing for Alzheimer’s candidate in 2023